GB2479799B - Methods for assessing LRRK2 inhibitors - Google Patents

Methods for assessing LRRK2 inhibitors

Info

Publication number
GB2479799B
GB2479799B GB201011010A GB201011010A GB2479799B GB 2479799 B GB2479799 B GB 2479799B GB 201011010 A GB201011010 A GB 201011010A GB 201011010 A GB201011010 A GB 201011010A GB 2479799 B GB2479799 B GB 2479799B
Authority
GB
United Kingdom
Prior art keywords
assessing
methods
lrrk2 inhibitors
lrrk2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB201011010A
Other versions
GB2479799A (en
GB201011010D0 (en
Inventor
Nicolas Dzamko
Dario Alessi
R Jeremy Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/763,005 external-priority patent/US20110256553A1/en
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to US12/828,674 priority Critical patent/US8367349B2/en
Publication of GB201011010D0 publication Critical patent/GB201011010D0/en
Priority to PCT/GB2011/050776 priority patent/WO2011131980A1/en
Priority to EP11720832A priority patent/EP2560995A1/en
Priority to JP2013505543A priority patent/JP2013524804A/en
Priority to CN2011800302006A priority patent/CN102947339A/en
Publication of GB2479799A publication Critical patent/GB2479799A/en
Publication of GB2479799B publication Critical patent/GB2479799B/en
Application granted granted Critical
Priority to US13/733,567 priority patent/US20130171661A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
GB201011010A 2010-04-19 2010-06-30 Methods for assessing LRRK2 inhibitors Expired - Fee Related GB2479799B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/828,674 US8367349B2 (en) 2010-04-19 2010-07-01 Methods for identifying modulators of LRRK2
CN2011800302006A CN102947339A (en) 2010-04-19 2011-04-19 Assay for identification of LRRK2 inhibitors
JP2013505543A JP2013524804A (en) 2010-04-19 2011-04-19 Assays for identifying LRRK2 inhibitors
EP11720832A EP2560995A1 (en) 2010-04-19 2011-04-19 Assay for identification of lrrk2 inhibitors
PCT/GB2011/050776 WO2011131980A1 (en) 2010-04-19 2011-04-19 Assay for identification of lrrk2 inhibitors
US13/733,567 US20130171661A1 (en) 2010-04-19 2013-01-03 Assay for Identification of LRRK2 Inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/763,005 US20110256553A1 (en) 2010-04-19 2010-04-19 Methods
GB1006502A GB2479736A (en) 2010-04-19 2010-04-19 Assay for testing effect of compound on Ser910/ Ser 935 phosphorylation of LRRK2, and/or binding of 14-3-3 polypeptide

Publications (3)

Publication Number Publication Date
GB201011010D0 GB201011010D0 (en) 2010-08-18
GB2479799A GB2479799A (en) 2011-10-26
GB2479799B true GB2479799B (en) 2012-09-19

Family

ID=42668974

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201011010A Expired - Fee Related GB2479799B (en) 2010-04-19 2010-06-30 Methods for assessing LRRK2 inhibitors

Country Status (1)

Country Link
GB (1) GB2479799B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769768A1 (en) 2019-07-23 2021-01-27 Consejo Superior de Investigaciones Cientificas (CSIC) Compounds useful for the treatment of parkinson s disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB2463656A (en) * 2008-09-18 2010-03-24 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB2463656A (en) * 2008-09-18 2010-03-24 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochem. J., Vol.424, 2009, Nichols, R. J. et al., "Substrate specificity and inhibitors of...", pp.47-60 *
J. Proteome Res., Vol.9, 2010, Gloeckner, C. J. et al., "Phosphopeptide analysis reveals two discrete...", pp.1738-1745 *

Also Published As

Publication number Publication date
GB2479799A (en) 2011-10-26
GB201011010D0 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
GB2498145B (en) Releasable corrosion inhibitors
HK1222647A1 (en) Kinase inhibitors
EP2710007A4 (en) Kinase inhibitors
ZA201307016B (en) Glucosylceramide synthase inhibitors
EP2683693A4 (en) Rorgammat inhibitors
EP2552208A4 (en) Imidazolyl-imidazoles as kinase inhibitors
EP2552211A4 (en) Indazolyl-pyrimidines as kinase inhibitors
EP2552214A4 (en) Pyrazolyl-pyrimidines as kinase inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
EP2785183A4 (en) Triazolopyridinone pde10 inhibitors
GB201009731D0 (en) Kinase inhibitors
IL229028A0 (en) Kinase inhibitors
FI3985979T3 (en) Method for determining reference unit
HK1199873A1 (en) Kinase inhibitors
EP2763533A4 (en) Triazolyl pde10 inhibitors
EP2701512A4 (en) Aldosterone synthase inhibitors
EP2539469A4 (en) Methods for determining gene-nutrient interactions
EP2629616A4 (en) Substituted amino-triazolyl pde10 inhibitors
GB201020798D0 (en) Corrosion inhibitors
IL217720A0 (en) Isoform selective phospholipase d inhibitors
PL2753928T3 (en) Compositions and methods for detecting autoantibodies
GB2479799B (en) Methods for assessing LRRK2 inhibitors
GB201018597D0 (en) Inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20140630